The bill inserts a new Section 27 into the Federal Trade Commission Act that creates a standalone unfair-competition claim for so-called product hopping: actions by a brand manufacturer to shift the market from an original (reference or listed) drug to a reformulation or modified biological product. It defines ‘‘hard’’ and ‘‘soft’’ switches, sets a specific window for presumptive liability tied to an ANDA or 351(k) filing, and allows the FTC to seek injunctive and monetary equitable relief in federal court.
This matters because it gives the FTC a statutory tool with a tailored burden-shifting framework to challenge strategies that can delay generic or biosimilar market entry. Brand drug companies, biosimilar and generic applicants, payers, and litigation counsels should expect new compliance, monitoring, and litigation dynamics if the provision becomes law.
At a Glance
What It Does
The bill creates a prima facie FTC claim for product hopping during the period from notice of an ANDA or biosimilar application to the earlier of 180 days after a generic/biosimilar first markets or three years after a follow-on product launches. It distinguishes ‘‘hard’’ switches (withdrawals/discontinuances or destruction of inventory tied to a follow-on) from ‘‘soft’’ switches (other actions that disadvantage the original product) and permits defendants to rebut liability with specified justifications.
Who It Affects
Brand pharmaceutical and biologic manufacturers that reformulate, relabel, discontinue, or otherwise change products; generic and biosimilar applicants that reference listed or reference products; the FTC, which gains direct court enforcement authority; and downstream stakeholders—payers, PBMs, and patients—who may see effects on drug availability and pricing.
Why It Matters
It codifies an enforcement pathway targeted at a practice antitrust enforcers have litigated for years, but often with mixed results in courts. The statute’s defined timelines, specific offenses, and remedies make product-hopping a clearer legal risk and could change how manufacturers time reformulations, withdrawals, and marketing changes.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 27 adds a focused anticompetitive-offense to the FTC Act that targets manufacturer conduct intended to thwart generic or biosimilar competition after a potential competitor files an ANDA or a 351(k) biosimilar application. The provision starts with precise definitions—what counts as a ‘‘follow-on product,’’ when a listed or reference drug is the relevant incumbent, and the delineation between a generic and a biosimilar application—so that the triggering event for the statute is an actual regulatory filing that references the brand product.
Once a filing is made, the statute establishes a defined window during which certain manufacturer actions will create a prima facie case of an unfair method of competition: from the brand’s receipt of notice of the applicant’s filing until the earlier of (a) 180 days after a generic/biosimilar first markets or (b) three years after the follow-on product is first marketed. Within that window, the bill treats two categories of conduct differently.
A ‘‘hard switch’’ covers cases where the manufacturer withdraws or discontinues the original product (or requests FDA withdraw approval or places the product on a discontinued list) and at the same time introduces a follow-on; it also covers destruction of incumbent inventory combined with launching the follow-on. A ‘‘soft switch’’ captures more subtle actions that disadvantage the incumbent product relative to the follow-on—examples would include changes to packaging, distribution, or promotion—that, together with marketing the follow-on, impede competitor entry.The statute is not absolute.
It creates a specific defense pathway: the manufacturer can show it would have taken the action regardless of the reference application and must also demonstrate a narrow set of justifications—patient safety for hard switches, unavoidable supply disruption for some withdrawals, or legitimate pro-competitive reasons for soft switches. The FTC can rebut those justifications and may prevail if it shows the anticompetitive harms outweigh any benefits or that less restrictive alternatives existed.
For enforcement the Commission can pursue administrative proceedings, seek temporary injunctions under district-court Section 13(b)-style authority, or bring suits for permanent injunctive relief and equitable monetary remedies including disgorgement and restitution (subject to offsets and a five-year limitations clock). The bill also preserves existing antitrust laws and authorizes FTC rulemaking to define any remaining terms.
The Five Things You Need to Know
Prima facie window: Liability presumptively arises from the date the brand receives notice of an ANDA or 351(k) filing until the earlier of 180 days after the first generic/biosimilar markets or three years after the follow-on product is marketed.
Hard switch vs soft switch: A hard switch requires withdrawal/discontinuance or destruction of incumbent product together with marketing a follow-on; a soft switch requires other actions that objectively disadvantage the incumbent plus marketing the follow-on.
Available defenses: Manufacturer can avoid liability by proving it would have acted regardless and by showing specific rationales—patient safety, uncontrollable supply disruption, or legitimate pro‑competitive reasons (for soft switches).
Enforcement and remedies: The FTC may use administrative proceedings or bring district-court suits for temporary or permanent injunctions and may seek disgorgement and restitution; disgorgement and restitution claims have a 5‑year lookback and disgorgement is offset by restitution.
Judicial review route: A manufacturer subject to a final FTC cease-and-desist order may petition for review within 30 days in the D.C. Circuit or the federal circuit where the manufacturer’s ultimate parent is incorporated; the FTC’s factual findings are conclusive if supported by evidence.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the ‘Drug Competition Enhancement Act.’ This is purely nominal but signals the statute’s policy focus on preserving competitive entry for generics and biosimilars.
Who and what the rule covers
Establishes critical statutory definitions: abbreviated new drug applications (ANDAs) and biosimilar 351(k) applications; the notion of a follow-on product (a reformulation or modification by the same manufacturer whose indication is identical or substantively similar); the listed drug/reference product; and the ultimate parent entity standard for venue. The follow-on-product definition explicitly excludes changes required by law or at FDA’s request, which narrows the statute to manufacturer-initiated modifications.
Creates a prima facie product-hopping claim and defines hard/soft switches
Sets out the prima facie rule tied to the filing-notice trigger and the two alternative time limits (180 days after first generic/biosimilar market entry or a three‑year cap after the follow-on’s market entry). It operationalizes ‘‘hard switch’’ (withdrawal/discontinuance or inventory destruction combined with marketing a follow-on) and ‘‘soft switch’’ (other conduct that unfairly disadvantages the incumbent). The provision allows objective circumstances to establish whether actions ‘‘impede competition,’’ but leaves factual content to enforcement proceedings.
Permitted conduct and the defendant’s burden to justify changes
Exempts truthful marketing and mere cessation of promotional marketing. For defendant manufacturers, the statute sets a two-part justification test: show the action would have occurred irrespective of a competitor’s filing and demonstrate a narrow category of reasons (safety, supply disruption beyond control, or legitimate pro‑competitive reasons). The Commission retains express authority to rebut those justifications by preponderance or on balance, including showing less anticompetitive alternatives were available.
FTC enforcement powers, remedies, and procedural pathways
Gives the FTC the choice of administrative proceedings, district-court temporary injunctions, or full civil suits for permanent relief, disgorgement, and restitution. Monetary remedies have a five-year limitations window and disgorgement must be offset by any restitution. The bill preserves existing antitrust law and authorizes the FTC to define remaining terms through notice-and-comment rulemaking under the Administrative Procedure Act.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Generic and biosimilar applicants — The statute reduces the payoff for brand tactics that delay market entry, improving prospects that an approved ANDA or 351(k) filer can reach the market without facing an orchestrated impediment from the incumbent manufacturer.
- Payers and PBMs — By targeting practices that preserve brand market exclusivity through reformulations, payers and administrators may face fewer artificial delays to lower-cost alternatives, which can reduce spending and improve formulary negotiating leverage.
- Patients and consumer advocates — If enforcement prevents blocking tactics, patients could gain earlier access to generics and biosimilars and experience lower out-of-pocket costs and improved access to therapies.
Who Bears the Cost
- Brand pharmaceutical and biologic manufacturers — Face increased legal risk (administrative and district-court exposure), potential disgorgement/restitution, and the need to redesign product transition strategies and document contemporaneous justifications.
- In-house and outside counsel — Anticipate expanded compliance work: new policies for withdrawals, inventory handling, marketing changes, and documentation to establish preexisting business plans or safety reasons.
- Courts and FTC resources — The statute is likely to generate new administrative proceedings and civil suits with complex factual records about marketing, supply chains, and clinical justifications, increasing litigation load and investigatory demands on the Commission.
Key Issues
The Core Tension
The central trade-off is straightforward but stark: deter brand tactics that unfairly block lower-cost generics and biosimilars, versus preserve the freedom for manufacturers to lawfully redesign, withdraw, or improve products for legitimate safety or competitive reasons; the statute builds defenses but leaves many judgment calls to the FTC and courts, so the law may either over-deter routine, patient‑beneficial changes or under-deter sophisticated exclusionary conduct.
The bill turns a previously fact-intensive and context-specific product-hopping inquiry into a structured statutory framework, but that structure creates new implementation questions. The prima facie window is keyed to the brand’s receipt of notice of an ANDA or 351(k) filing; in practice, proving when the brand ‘‘received notice’’ and how many competitors’ filings trigger the clock will require granular discovery.
The dual timing rule (180 days after first generic/biosimilar launch or three years after follow-on launch) attempts to balance early competitive entry against staggered product strategies, yet it creates opportunities for strategic timing—e.g., a brand could delay or accelerate market actions to shift which clock governs. Those calendar mechanics could become litigation focal points.
The statutory defenses are narrowly drafted but hinge on contested factual showings. ‘‘Legitimate pro‑competitive reasons’’ for a soft switch and ‘‘safety’’ for a hard switch are open-ended phrases whose contours will be developed in FTC proceedings and courts. The bill allows the FTC to weigh pro‑competitive benefits against harms and to demand less-attributable alternatives, raising the prospect of second-guessing clinical or commercial judgments.
There is also potential for perverse incentives: an overly aggressive enforcement posture could chill beneficial reformulations that improve adherence or safety, while an underenforced statute could invite regulatory gaming, where mere filing of an ANDA becomes a tool to provoke costly disputes. Finally, the interplay between this new standalone claim and existing antitrust doctrine—including monopolization and sham‑petitioning principles—remains unsettled, even though the bill preserves antitrust law; overlap will create complex litigation strategies and appeals.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.